Hematopoiesis News Volume 2.48 | Dec 6 2011

Erythroid/Myeloid Progenitors and Hematopoietic Stem Cells Originate from Distinct Populations of Endothelial Cells
Here scientists show that the requirements for core binding factor β in erythroid/myeloid progenitor and hematopoietic stem cell formation in the conceptus are temporally and spatially distinct. [Cell Stem Cell] Abstract

PDGF-BB Modulates Hematopoiesis and Tumor Angiogenesis by Inducing Erythropoietin Production in Stromal Cells
Here researchers show in mouse tumor models that platelet-derived growth factor-BB (PDGF-BB) induces erythropoietin mRNA and protein expression by targeting stromal and perivascular cells that express PDGF receptor-β. [Nat Med] Abstract

Inhibiting the Palmitoylation/Depalmitoylation Cycle Selectively Reduces the Growth of Hematopoietic Cells Expressing Oncogenic Nras
The palmitoylation/depalmitoylation cycle of post-translational processing is a potential therapeutic target for selectively inhibiting the growth of hematologic cancers with somatic NRAS mutations. To investigate this question at the single cell level, investigators constructed murine stem cell virus vectors and assayed the growth of myeloid progenitors. [Blood] Abstract

Durable Donor Engraftment After Radioimmunotherapy Using Alpha-Emitter Astatine-211–Labeled Anti-CD45 Antibody for Conditioning in Allogeneic Hematopoietic Cell Transplantation
To reduce toxicity associated with external γ-beam radiation, scientists investigated radioimmunotherapy with an anti-CD45 monoclonal antibody labeled with the α emitter, astatine 211, as a conditioning regimen in dog leukocyte antigen-identical hematopoietic cell transplantation. [Blood] Abstract

Expansion of Functionally Defined Mouse Hematopoietic Stem/Progenitor Cells by a Short Isoform of RUNX1/AML1
Findings establish the short isoform of RUNX1/AML1 as an isoform-specific molecule that can influence several transcriptional regulators associated with hematopoietic stem cells, leading to enhanced self-renewal activity and hematopoietic stem/progenitor cell expansion ex vivo and in vivo. [Blood] Abstract

The Dual mTORC1 and mTORC2 Inhibitor AZD8055 Has Anti-Tumor Activity in Acute Myeloid Leukemia
Researchers show that the specific mammalian target of rapamycin (mTOR) kinase inhibitor AZD8055 blocked mTORC1 and mTORC2 signaling in acute myeloid leukemia. [Leukemia] Abstract

3D Co-Culture of Hematopoietic Stem and Progenitor Cells and Mesenchymal Stem Cells in Collagen Scaffolds as a Model of the Hematopoietic Niche
Here, investigators propose a collagen-based three-dimensional (3D) environment for hematopoietic stem and progenitor cells with mesenchymal stem cells derived either from bone marrow (BM) or umbilical cord, to recapitulate the main components of the BM niche. [Biomaterials] Abstract

Inability of Human iPSC-Hematopoietic Derivatives to Downregulate miRNAs In Vivo Reveals a Block in Xenograft Hematopoietic Regeneration
Here scientists show that, unlike primitive hematopoietic cells derived from human embryonic stem cells, phenotypically identical cells derived from human induced pluripotent stem cells (iPSCs) are more permissive to graft the bone marrow of xenotransplantation recipients. [Stem Cells] Abstract

The JAK Inhibitor AZD1480 Regulates Proliferation and Immunity in Hodgkin Lymphoma
Researchers investigated the activity of the Janus kinase (JAK) inhibitor AZD1480 in Hodgkin lymphoma-derived cell lines and determined its mechanisms of action. [Blood Cancer J] Abstract

CLINICAL RESEARCH

Nonmalignant Late Effects and Compromised Functional Status in Survivors of Hematopoietic Cell Transplantation
The objective of this study was to describe the incidence of nonmalignant late complications and their association with health and functional status in a recent cohort of hematopoietic cell transplantation survivors. [J Clin Oncol] Abstract

Hematological Cancer: Gene Classifier Helps Identify Therapy for Leukemia
Scientists have developed a 38-gene classifier that can accurately predict patients who are at risk of developing leukemia. [Nat Rev Clin Oncol] Abstract

A Phase I Dose-Escalation Study of ARRY-520, a Kinesin Spindle Protein Inhibitor, in Patients with Advanced Myeloid Leukemias
A phase I trial was conducted to establish the safety and the maximum tolerated dose of ARRY-520 given as a 1-hour infusion in either a single dose or on a day 1, 3, and 5 divided-dose schedule per cycle in patients with advanced or refractory myeloid leukemias. [Cancer] Abstract

Emergent BioSolutions Receives Orphan Drug Designation for its TRU-016 Protein Therapeutic for the Treatment of Chronic Lymphocytic Leukemia
Emergent BioSolutions Inc. announced that its humanized anti-CD37 mono-specific protein therapeutic, TRU-016, in development for the treatment of B-cell malignancies has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of chronic lymphocytic leukemia patients. [Emergent BioSolutions, Inc.] Press Release

Genmab Announces Appeal of US Court Judgment in Favor of Arzerra in Patent Infringement Lawsuit
Genmab A/S announced that Genentech and Biogen Idec have appealed the judgment in favor of GlaxoSmithKline (GSK) in a patent infringement case involving Arzerra brought against GSK by Genentech and Biogen Idec. [Genmab A/S] Press Release

NICE Recommends Two Drugs for Chronic Myeloid Leukemia
In new draft guidance, the National Institute for Health and Clinical Excellence (NICE) has recommended nilotinib (Tasigna) and imatinib (Glivec), both made by Novartis, for the first line treatment of chronic myeloid leukemia. Dasatinib (Sprycel), made by Bristol-Myers Squibb is not recommended. [National Institute for Health and Clinical Excellence, United Kingdom] Press Release

Small Grants Program for Cancer Epidemiology (R03) (PAR-12-039) [National Institutes of Health, United States]

Identifying Heart, Lung, and Blood Disease-Causing Variants (R01) (PARP-12-043) [National Institutes of Health, United States]

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoietic community

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Research Technologist, Manufacturing Sciences (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Marie Curie Experienced Researcher (Alexander Fleming Biomedical Sciences Research Center)

Postdoctoral Position – Center for Human Genetics (VIB Research Institute)

Postgraduate Students (Masaryk University)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.